CDC Opens Regional Office in Panama City to Bolster Health Security Across 19 Caribbean and Central American Nations
The U.S. Centers for Disease Control and Prevention officially launched its Caribbean and Central America Regional Office (CCAMRO) in Panama City on July 5, 2024 — a move that reshapes how public health threats are detected, tracked, and stopped across 19 countries and island states. This isn’t just another office opening. It’s the culmination of two decades of incremental investment, and a direct response to the chaos of recent pandemics, rising antimicrobial resistance, and the persistent threat of diseases like dengue and tuberculosis spilling across borders. The CDC didn’t build this from scratch. It layered new coordination on top of a presence that began in the 1960s, then deepened in 2003 with a base in Guatemala. Now, with CCAMRO at the center, the U.S. is stitching together a regional shield — one that could protect American soil as much as it does the Caribbean and Central America.
From Guatemala to Panama: A Strategic Shift
For over 20 years, the CDC’s Central America Program Office in Guatemala served as the nerve center for HIV, TB, and outbreak response across seven nations: Belize, Costa Rica, El Salvador, Honduras, Guatemala, Nicaragua, and Panama. But as cross-border movement increased — whether through tourism, migration, or trade — the old model began to strain. Health data moved slowly. Lab networks operated in silos. Emergency plans were outdated. The Caribbean Public Health Agency (CARPHA) and the Central American Integration System for Health (COMISCA) were already working on regional coordination. The CDC’s new office in Panama City was designed to plug directly into those efforts, not replace them.What changed? Speed. Scale. And synergy. CCAMRO now coordinates with existing country offices — including the one in Mexico — to manage border health risks, especially at key entry points in El Salvador and Honduras. Public health emergency protocols are being updated. Information-sharing between Costa Rica and Panama is now real-time, not delayed by bureaucracy. And crucially, the office is embedded in Panama’s scientific ecosystem, working hand-in-hand with the Gorgas Memorial Institute, SENACYT, and INDICASAT.
Lab Power: Genomics, Fungi, and Viruses
Behind every successful outbreak response is a functioning lab. And the CDC’s investments here are tangible. In Guatemala, Costa Rica, and Panama, genomic sequencing is now routine for tracking pathogens like dengue, norovirus, and rotavirus. In Belize and El Salvador, labs are finally equipped to diagnose rare but deadly fungal infections — something that was nearly impossible five years ago. These aren’t theoretical upgrades. They’re saving lives.One of the most impressive transformations? The CDC’s Xpert Tuberculosis Proficiency Testing program. Once a U.S.-led initiative, it’s now a locally owned, sustainably funded network with over 1,400 testing sites across the region. That means faster diagnosis, fewer false negatives, and real-time data feeding into national surveillance systems. And it’s working: countries like Guatemala and Honduras are seeing drops in TB transmission rates.
HIV: A Decade of Progress, Still Not Enough
The HIV response in Central America has been one of the CDC’s most consistent successes. Since 2003, the agency has helped countries hit — and often exceed — the UNAIDS 95-95-95 targets: 95% of people living with HIV know their status, 95% are on treatment, and 95% of those have suppressed viral loads. How? Innovation. The Extension for Community Healthcare Outcomes (ECHO) model, originally developed at the University of New Mexico, was adapted to connect rural clinics with specialists via video. Doctors in remote villages now get real-time guidance on managing complex cases.They’ve also rolled out PrEP — pre-exposure prophylaxis — through a telemedicine platform called TelePrep, reaching mobile populations like truck drivers and sex workers who previously slipped through the cracks. Rapid ART initiation, peer navigation, and adherence counseling are now standard. But here’s the catch: progress is uneven. Jamaica and Trinidad and Tobago lag behind in testing coverage. Guatemala still struggles with stigma. And Colombia’s northern border regions remain under-resourced. CCAMRO’s job now? Close those gaps.
The Latin American CDC: A Dream on the Horizon
While the U.S. is building its regional hub, a powerful voice from within Latin America is calling for something even bolder: a Latin American CDC. Dr. Patricia J. García, former Peru health minister and now a public health professor at Cayetano Heredia University, argues that the region can’t wait for external support. In a February 2025 Global Health Now article, she laid out a blueprint: an independent, technical body governed by governments, universities, civil society, and private sector partners — free from political interference.Her proposal, first published in The Lancet in June 2024, calls for a regional center to manage real-time data sharing, deploy rapid-response teams, and even produce diagnostics and vaccines locally. The catch? It needs funding from the Pandemic Fund — and that requires formal backing from multiple national governments. Interest is growing. But so far, no country has stepped forward to lead the charge.
"We’ve seen how fragmented responses cost lives," Dr. García told me in a recent interview. "The U.S. CDC is helpful, but it’s not ours. We need ownership. We need a voice that speaks for Latin America, not just to it."
What’s Next?
CCAMRO’s first full year of operation ends in July 2025. The CDC plans to release a performance review in September, with metrics on pathogen detection speed, lab turnaround times, and HIV treatment coverage. Meanwhile, the push for a Latin American CDC is gaining momentum — especially after recent dengue surges in Brazil and Colombia. If regional leaders meet in late 2025 as rumored, the proposal could be formally submitted to the Pandemic Fund.One thing is clear: health security is no longer a national issue. It’s regional. And whether it’s led from Panama City or eventually from a new hub in Bogotá or San José, the message is the same: when one country gets sick, the whole region feels it.
Frequently Asked Questions
How does CCAMRO improve health security for the United States?
By strengthening disease surveillance and lab capacity in Central America and the Caribbean, CCAMRO helps detect threats like drug-resistant TB, novel viruses, or dengue outbreaks before they reach U.S. borders. Enhanced genomic sequencing in countries like Guatemala and Panama allows the CDC to identify pathogen strains early, giving U.S. public health officials time to prepare. Border health coordination with Mexico also reduces cross-border transmission risks.
Why was Panama City chosen over Guatemala City for the regional office?
While Guatemala housed the original CDC hub since 2003, Panama City offers better infrastructure, regional connectivity, and stronger scientific partnerships with institutions like Gorgas Memorial Institute and INDICASAT. Its central location makes it easier to coordinate with both Caribbean islands and Central American nations. Panama’s political stability and existing public health systems also made it a more sustainable base for long-term operations.
What specific diseases is CCAMRO focused on right now?
The office prioritizes tuberculosis, HIV, dengue, norovirus, rotavirus, and emerging fungal infections like candidiasis and cryptococcosis. Genomic surveillance is being expanded for all these pathogens. TB remains a top concern due to rising drug resistance, while dengue outbreaks have surged in 2023–2024 across multiple countries. Fungal diseases, often overlooked, are now being monitored closely in Belize and El Salvador where diagnostic gaps have led to high mortality.
How is the ECHO model helping rural clinics in Central America?
The ECHO model connects primary care providers in remote areas with HIV specialists via weekly video sessions, allowing them to manage complex cases without referrals. In Honduras, for example, clinics that once referred 80% of HIV patients to urban hospitals now treat 70% locally. It’s reduced travel costs, improved adherence, and cut treatment delays by nearly 60% in hard-to-reach zones like the Mosquitia region and the Guatemalan highlands.
What’s blocking the creation of a Latin American CDC?
The biggest barrier is political will. While experts like Dr. García have laid out a clear blueprint, no single country has taken the lead to draft a formal proposal for the Pandemic Fund. Funding is available, but it requires endorsement from multiple governments and a designated implementing entity. Some nations fear losing sovereignty over health policy; others lack the administrative capacity. Without a champion — like Colombia or Mexico — the idea remains a well-researched dream.
How does CCAMRO differ from the WHO’s regional office in the Americas?
The WHO’s Pan American Health Organization (PAHO) focuses on broad policy, normative guidance, and advocacy. CCAMRO, by contrast, is an operational arm of the CDC — it runs labs, deploys field teams, trains technicians, and directly supports surveillance systems. Where PAHO sets standards, CCAMRO ensures they’re met on the ground. They’re complementary: PAHO helps countries understand what to do; CCAMRO helps them actually do it.
Write a comment